Heart failure & cardiomyopathiesRandomised controlled trial
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
- Baseline characteristics report of the ODYSSEY-HCM randomised controlled trial
- phase 3
- double-blind
- placebo-controlled
- 201 sites worldwide
- blinded core laboratory dose titration
Study context
- Population
- Symptomatic adults with nonobstructive hypertrophic cardiomyopathy (nHCM)1,088 screened
- Participants
- 580 adults
- Comparison
- Mavacamten vs placebo
- Primary endpoint
- Changes in KCCQ-23 Clinical Summary Score and in peak oxygen consumption (pVO2) on cardiopulmonary exercise testing
- Follow-up
- Baseline to week 48
Primary result
As reported in the abstract
Baseline characteristics · baseline
- Age, mean ± SD (years)
- 56 ± 15
- Women
- 46%
- Family history
- 43%
- NYHA class II
- 70%
- NYHA class III
- 30%
- KCCQ-23 Clinical Summary Score, mean
- 58 ± 20
- On beta-blockers
- 77%
- LVEF, mean
- 66% ± 4%
- pVO2, mean (mL/kg/min)
- 18 ± 6
Original publication
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. JACC Heart Fail. doi:10.1016/j.jchf.2024.11.013
Summarised from the published abstract; every number is checked against it